NZ512968A - Methods of using a neurotrophin and its analogues for the treatment of gastrointestinal hypomotility disorders - Google Patents

Methods of using a neurotrophin and its analogues for the treatment of gastrointestinal hypomotility disorders

Info

Publication number
NZ512968A
NZ512968A NZ512968A NZ51296800A NZ512968A NZ 512968 A NZ512968 A NZ 512968A NZ 512968 A NZ512968 A NZ 512968A NZ 51296800 A NZ51296800 A NZ 51296800A NZ 512968 A NZ512968 A NZ 512968A
Authority
NZ
New Zealand
Prior art keywords
use according
neurotrophin
receptor
treatment
gastrointestinal
Prior art date
Application number
NZ512968A
Other languages
English (en)
Inventor
Jesse M Cedarbaum
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of NZ512968A publication Critical patent/NZ512968A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
NZ512968A 1999-01-15 2000-01-11 Methods of using a neurotrophin and its analogues for the treatment of gastrointestinal hypomotility disorders NZ512968A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/232,171 US6656474B1 (en) 1999-01-15 1999-01-15 Methods of using a neurotrophin and its analogues for the treatment of gastrointestinal hypomotility disorders
PCT/US2000/000682 WO2000041719A1 (en) 1999-01-15 2000-01-11 Methods of using a neurotrophin and its analogues for the treatment of gastrointestinal hypomotility disorders

Publications (1)

Publication Number Publication Date
NZ512968A true NZ512968A (en) 2003-09-26

Family

ID=22872143

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ512968A NZ512968A (en) 1999-01-15 2000-01-11 Methods of using a neurotrophin and its analogues for the treatment of gastrointestinal hypomotility disorders

Country Status (13)

Country Link
US (1) US6656474B1 (enExample)
EP (1) EP1146899B1 (enExample)
JP (1) JP4489303B2 (enExample)
AT (1) ATE345811T1 (enExample)
AU (1) AU775860B2 (enExample)
CA (1) CA2360252C (enExample)
DE (1) DE60031951D1 (enExample)
IL (2) IL144315A0 (enExample)
NO (1) NO329488B1 (enExample)
NZ (1) NZ512968A (enExample)
TR (2) TR200102767T2 (enExample)
WO (1) WO2000041719A1 (enExample)
ZA (1) ZA200105799B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040082509A1 (en) 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US8183339B1 (en) 1999-10-12 2012-05-22 Xigen S.A. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
MXPA02012602A (es) * 2000-06-22 2003-05-14 Genentech Inc Anticuerpos monoclonales agonistas anti-trk-c.
US20040086532A1 (en) * 2002-11-05 2004-05-06 Allergan, Inc., Botulinum toxin formulations for oral administration
JP2006520806A (ja) * 2003-03-20 2006-09-14 ライナット ニューロサイエンス コーポレイション タキソール誘導性腸障害を処置する方法
WO2007031098A1 (en) 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
US7943328B1 (en) 2006-03-03 2011-05-17 Prometheus Laboratories Inc. Method and system for assisting in diagnosing irritable bowel syndrome
US20100094560A1 (en) * 2006-08-15 2010-04-15 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
US20080085524A1 (en) * 2006-08-15 2008-04-10 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
WO2009143865A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2009143864A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
WO2010072228A1 (en) 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
WO2011160653A1 (en) 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
CA2807036C (en) 2010-10-14 2018-01-16 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
AU2014301631A1 (en) 2013-06-26 2015-08-27 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4987136A (en) * 1982-03-16 1991-01-22 The Rockefeller University Method for controlling gastrointestinal dysmotility
US5962404A (en) * 1989-08-28 1999-10-05 Yeda Research & Development Co., Ltd. Enzymatically-produced oligodendrocyte cytotoxic dimeric IL-2 factor
US6174701B1 (en) * 1989-12-12 2001-01-16 Genentech, Inc. Neuronal factor
AU4920893A (en) * 1992-09-14 1994-04-12 Regeneron Pharmaceuticals, Inc. Method of producing analgesia using neurotrophins
US5753225A (en) 1993-12-03 1998-05-19 The Regents Of The University Of California Antibodies that mimic actions of neurotrophins
CA2188017C (en) * 1994-04-25 2010-09-28 Joffre Baker Cardiotrophin and uses therefor
US5759775A (en) * 1994-10-27 1998-06-02 Genetech, Inc. Methods for detecting nucleic acids encoding AL--1 neurotrophic factor
US5770577A (en) * 1994-11-14 1998-06-23 Amgen Inc. BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
US6211142B1 (en) 1995-03-10 2001-04-03 Genentech, Inc. Compositions comprising gas6 polypeptides and articles of manufacture comprising the same
US5616724A (en) * 1996-02-21 1997-04-01 Cephalon, Inc. Fused pyrrolo[2,3-c]carbazole-6-ones
JP3540912B2 (ja) * 1997-03-28 2004-07-07 京セラ株式会社 釣糸用ガイド部材
WO1998049308A1 (en) 1997-04-25 1998-11-05 Genentech, Inc. Ngf variants
US6284540B1 (en) * 1998-09-29 2001-09-04 Washington University Artemin, a novel neurotrophic factor

Also Published As

Publication number Publication date
TR200201875T2 (tr) 2002-09-23
NO20013493D0 (no) 2001-07-13
CA2360252C (en) 2010-11-02
ZA200105799B (en) 2002-01-24
CA2360252A1 (en) 2000-07-20
IL144315A (en) 2008-08-07
NO20013493L (no) 2001-09-17
IL144315A0 (en) 2002-05-23
JP4489303B2 (ja) 2010-06-23
EP1146899A1 (en) 2001-10-24
JP2002534479A (ja) 2002-10-15
AU2963600A (en) 2000-08-01
TR200102767T2 (tr) 2002-04-22
EP1146899B1 (en) 2006-11-22
DE60031951D1 (de) 2007-01-04
EP1146899A4 (en) 2003-03-05
ATE345811T1 (de) 2006-12-15
NO329488B1 (no) 2010-10-25
AU775860B2 (en) 2004-08-19
US6656474B1 (en) 2003-12-02
WO2000041719A9 (en) 2001-08-30
WO2000041719A1 (en) 2000-07-20

Similar Documents

Publication Publication Date Title
US6656474B1 (en) Methods of using a neurotrophin and its analogues for the treatment of gastrointestinal hypomotility disorders
ES2304811T3 (es) Fragmentos del factor de crecimiento de tejido conjuntivo.
CN1723039B (zh) 抗神经生长因子抗体拮抗剂在制备治疗手术后疼痛的药物中的应用
ES2363162T3 (es) Composicones y procedimientos para el tratamiento de trastornos fibróticos.
EP1156820B1 (en) Use of vascular endothelial growth factor-2 (vegf-2)
JP5669728B2 (ja) ニューロメジンｕ誘導体
EP2206721A1 (en) Neuromedin u derivative
US20030008822A1 (en) Use of IL-18 inhibitors for the treatment or prevention of sepsis
US20090317394A1 (en) Vascular endothelial growth factor-2
US20120149635A1 (en) Treatment for obesity
KR20010099807A (ko) 감마 인터페론에 대한 인간화 항체
CZ291047B6 (cs) Farmaceutický prostředek obsahující antagonisty faktoru růstu vaskulárních endoteliálních buněk
JP2006525960A (ja) 神経成長因子アゴニストおよびｎｓａｉｄ、ならびにこれらを含む組成物の投与によって疼痛を処置するための方法
EP4358995B1 (en) A myostatin pathway inhibitor in combination with a glp-1 pathway activator for use in treating metabolic disorders
CA2462459C (en) Copolymers for suppression of autoimmune diseases, and methods of use
NO326905B1 (no) Reversering av viral-indusert systemisk sjokk og andenod ved blokkering av lymfotoksin-<beta>-veien
JP2003507011A (ja) Ｉｌ−１６拮抗剤
BG66395B1 (bg) Използване на il-18 инхибитори за лечение или предпазване от увреждания на централната нервна система
CA2614171C (en) Copolymers for suppression of autoimmune diseases, and methods of use
JP4149713B2 (ja) 感染症治療剤
WO1994025483A1 (en) Immunotherapeutic peptides derived from toxic shock syndrome toxin-1, antibodies thereto, their uses in pharmaceutical compositions and diagnosis
AU2002309887B2 (en) Use of IL-18 inhibitors for the treatment or prevention of sepsis
CA2768340A1 (en) Copolymers for suppression of autoimmune diseases, and methods of use
Henderson et al. Localization of CNTF immunoreactivity to neurons and astroglia
JPH1121298A (ja) 知覚過敏抑制ペプチド

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 7 YEARS UNTIL 11 JAN 2020 BY COMPUTER PACKAGES INC

Effective date: 20130126

EXPY Patent expired